Cantor Fitzgerald Raises Earnings Estimates for Omeros

Key Points

• Cantor Fitzgerald raised its FY2025 earnings per share estimate for Omeros to ($1.69), up from a previous forecast of ($2.14), while the consensus estimate for the full year is ($3.09) per share.
• Omeros reported earnings of ($0.53) per share for the last quarter, slightly exceeding analysts' expectations, with revenue of $28.60 million compared to a consensus estimate of $0.31 million.
• The stock's current market capitalization is approximately $269.28 million with shares opening at $4.36, reflecting a 3.3% increase.

Omeros Corporation (NASDAQ:OMER - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Omeros in a note issued to investors on Monday, August 18th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will earn ($1.69) per share for the year, up from their previous forecast of ($2.14). The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros' FY2026 earnings at ($0.97) EPS.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02. The firm had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million.

Several other equities research analysts have also recently issued reports on OMER. HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Omeros in a report on Friday, June 27th. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research report on Friday, August 15th. D. Boral Capital reissued a "buy" rating and issued a $36.00 price target on shares of Omeros in a research note on Friday, August 15th. Finally, Wall Street Zen cut Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Omeros has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Price Performance

OMER stock traded down $0.08 during midday trading on Wednesday, hitting $4.40. The stock had a trading volume of 928,843 shares, compared to its average volume of 1,693,641. The firm has a market cap of $299.45 million, a PE ratio of -2.09 and a beta of 2.26. Omeros has a 12-month low of $2.95 and a 12-month high of $13.60. The company's 50-day moving average price is $3.66 and its 200 day moving average price is $5.61.

Institutional Investors Weigh In On Omeros

Several institutional investors have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. purchased a new position in shares of Omeros in the 2nd quarter valued at $32,000. Harbour Investments Inc. increased its holdings in Omeros by 46.1% in the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company's stock valued at $40,000 after purchasing an additional 4,251 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock valued at $40,000 after purchasing an additional 11,971 shares during the period. Sei Investments Co. purchased a new position in Omeros in the second quarter valued at about $40,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 1,972 shares in the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.